Investor Relations
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>
May 02, 2018
OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018 MORE >>
May 01, 2018
OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories MORE >>

Press Releases

All Releases
OPKO Presents Additional Data on RAYALDEE® at ENDO 2016
Apr 01, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) , announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Endocrine Society's 98 th Annual Meeting, underway in Boston, MA.
OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease
Mar 31, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) , announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Vitamin D Workshop , underway in Boston, MA.
OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application
Mar 30, 2016
Sole issue relates to third-party manufacturing observations No new clinical studies requested No safety or efficacy issues identified Management to host conference call today at 8:30 a.m. Eastern time MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) announces that the U.S.
OPKO Health Announces Executive Appointment
Mar 28, 2016
Ronald Trust , Ph.D., MBA, Appointed Vice President of Regulatory Affairs MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) today announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals . Prior to joining OPKO, Ron held senior
OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016
Mar 24, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced it will present 18-24 month clinical data from its ongoing open label extension study for hGH-CTP in an oral presentation at the Endocrine Society's 98 th Annual Meeting to be held April 1-4, 2016 , in Boston, MA.
OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes
Mar 16, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced dosing of the first subject in a Phase 1 single dose escalation study evaluating the safety and pharmacokinetics of a long-acting Oxyntomodulin (MOD-6031) in healthy, overweight or obese subjects.
OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines
Mar 15, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with
OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories
Mar 15, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announces the appointment of Gregory Henderson , M.D., Ph.D., as President of Bio-Reference Laboratories (BRL), effective immediately. Dr. Henderson succeeds Marc Grodman , M.D., who is resigning, having served as Chairman, President and CEO of
OPKO Health to Present at the 2016 Barclays Global Healthcare Conference
Mar 07, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Barclays Global Healthcare Conference in Miami, Florida on Wednesday, March 16, 2016 at 4:50 PM (ET) . The presentation will be webcast on the OPKO Investor Relations page of the
OPKO's GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting
Mar 02, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. announced today that its GeneDx subsidiary and business unit has been selected to give 11 platform talks and 18 poster presentations on a range of genetics-related topics at the 2016 American College of Medical Genetics and Genomics (ACMG) Annual Meeting.
OPKO Announces Financial and Operating Results
Feb 29, 2016
Consolidated Revenue Increased to $276.2 Million From $25.5 Million for the Three Months Ended December 31, 2015 , and Increased to $491.7 Million from $91.1 Million for the Year Ended December 31, 2015 Clinical Utility Study Demonstrates 4Kscore® Test Reduces Number of Unnecessary Prostate
OPKO's GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco
Feb 24, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK ) announced today that GeneDx was invited to participate in the Molecular Medicine Tri-Conference 2016, being held at the Moscone North Convention Center in San Francisco, California from March 6 th - 11 th , 2016, and will also be exhibiting
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
Feb 23, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced dosing of the first patient in a Phase 2a study evaluating the safety of a long-acting Factor VIIa in hemophilia patients. The Phase 2a study is a dose escalation study to determine safety and explore efficacy endpoints in
OPKO to Announce 2015 Fourth Quarter and Full Year Financial Results on February 29, 2016
Feb 23, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three and 12 months ended December 31, 2015 after the close of the U.S. financial markets on Monday, February 29, 2016 .
OPKO Health to Present at the RBC Capital Markets Global Healthcare Conference
Feb 18, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 23, 2016 at 3:05 PM (EST) . The presentation will be webcast on the OPKO Investor Relations page of the
Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer
Feb 09, 2016
4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) announced today the results of a study for the 4Kscore® Test's clinical utility in
OPKO's GeneDx to Present at Personalized Medicine World Conference
Jan 22, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman , MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year's  Personalized Medicine World Conference , Silicon Valley . Dr.
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference
Jan 06, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the J.P. Morgan 34 th Annual Healthcare Conference on Tuesday, January 12, 2016 at 4:00 PM (PT) . The presentation will be webcast on the OPKO Investor Relations page of the corporate
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Jan 05, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) today announced that the Company's 3.0% Convertible Senior Notes due 2033 (the "Notes") continue to be convertible by holders of such Notes through March 31, 2016 . The Company has elected to satisfy its conversion obligation under the Notes
OPKO's GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer Panel Reveals New Risks
Dec 21, 2015
Largest Published Study to Date Supports Testing Changes and Development of New Treatment Options MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. ( NYSE : OPK) through its subsidiary GeneDx, today announced results from the largest published study to date of patients who received hereditary genetic
Displaying 81 - 100 of 353